Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective

被引：19
|
作者：
Pizevska, Maja [1 ]
Kaeda, Jaspal [2 ]
Fritsche, Enrico [2 ]
Elazaly, Hisham [1 ]
Reinke, Petra [1 ,2 ]
Amini, Leila [1 ,2 ]
机构：
[1] Charite Univ Med Berlin, Berlin Inst Hlth, Ctr Regenerat Therapies, Berlin, Germany
[2] Charite Univ Med Berlin, Berlin Ctr Adv Therapies BeCAT, Berlin, Germany
来源：
FRONTIERS IN MEDICINE | 2022年 / 9卷
基金：
欧盟地平线“2020”;
关键词：
regulatory affairs; European Medicines Agency; legislation; regulatory science; Paul-Ehrlich-Institute (PEI); advanced therapy medicinal product (ATMP); cell and gene therapies; REGULATORY PATHWAYS; GENE THERAPIES; CELL; CHALLENGES; INNOVATION; SCIENCE;
D O I：
10.3389/fmed.2022.757647
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Advanced Therapy Medicinal Products (ATMPs) comprising cell, gene, and tissue-engineered therapies have demonstrated enormous therapeutic benefits. However, their development is complex to be managed efficiently within currently existing regulatory frameworks. Legislation and regulation requirements for ATMPs must strike a balance between the patient safety while promoting innovations to optimize exploitation of these novel therapeutics. This paradox highlights the importance of on-going dynamic dialogue between all stakeholders and regulatory science to facilitate the development of pragmatic ATMP regulatory guidelines.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Education for the translation of Advanced Therapy Medicinal Products
    Adamo, Davide
    Attico, Eustachio
    Pellegrini, Graziella
    FRONTIERS IN MEDICINE, 2023, 10
  • [2] REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE
    Hanna, E.
    Marre, C.
    Toumi, M.
    VALUE IN HEALTH, 2018, 21 : S202 - S203
  • [3] Access Challenges of Advanced Therapy Medicinal Products in Europe
    Szulc, E.
    Tschumi, B.
    Pennese, N.
    Lecureuil, C.
    Robbins, S.
    VALUE IN HEALTH, 2022, 25 (12) : S336 - S336
  • [4] THE REIMBURSEMENT STATUS OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE
    Hanna, E.
    Marre, C.
    Toumi, M.
    VALUE IN HEALTH, 2019, 22 : S428 - S428
  • [5] Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective
    Salmikangas, Paula
    Schuessler-Lenz, Martina
    Ruiz, Sol
    Celis, Patrick
    Reischl, Ilona
    Menezes-Ferreira, Margarida
    Flory, Egbert
    Renner, Matthias
    Ferry, Nicolas
    REGULATORY ASPECTS OF GENE THERAPY AND CELL THERAPY PRODUCTS: A GLOBAL PERSPECTIVE, 2015, 871 : 103 - 130
  • [6] Editorial: Clinical Translation and Commercialisation of Advanced Therapy Medicinal Products
    Martin, Ivan
    Bayon, Yves
    Yu, Tracy T. L.
    Vertes, Alain A.
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2020, 8 (08):
  • [7] THE REGULATION OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE AND THE ROLE OF ACADEMIA
    Pearce, K. F.
    Hildebrandt, M. O.
    Scheding, S.
    Koehl, U.
    Mischak-Weissinger, E.
    Hauser, A.
    Edinger, M.
    Greinix, H.
    Worel, N.
    Apperley, J.
    Lowdell, M. W.
    Dickinson, A. M.
    CYTOTHERAPY, 2013, 15 (04) : S51 - S52
  • [8] The regulation of advanced therapy medicinal products in Europe and the role of academia
    Lowdell, M. W.
    Pearce, K. F.
    Apperley, J.
    Dickinson, A. M.
    Edinger, M.
    Greinix, H.
    Hauser, A.
    Koehl, U.
    Mischak-Weissinger, E.
    Scheding, S.
    Worel, N.
    Hildebrandt, M.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S510 - S510
  • [9] Europe's Advanced Therapy Medicinal Products: chances and challenges
    Mertsching, Heike
    Walles, Thorsten
    EXPERT REVIEW OF MEDICAL DEVICES, 2009, 6 (02) : 109 - 110
  • [10] ADVANCED THERAPY MEDICINAL PRODUCTS (ATMPs): DEVELOPMENT AND REGULATION IN EUROPE
    Tsiftsoglou, Asterios S.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 50 : E42 - E42
12345